Search Results
Oct 21, 2025, 19:30 ET PADCEV™ (enfortumab vedotin-ejfv) Plus KEYTRUDA® (pembrolizumab) sBLA Granted FDA Priority Review for Treatment of Certain Patients with Muscle-Invasive Bladder Cancer
aminotransferase (AST), increased creatinine, rash, increased glucose, PN, increased lipase, decreased lymphocytes, increased alanine aminotransferase (ALT), decreased hemoglobin, fatigue, decreased sodium, decreased phosphate, decreased albumin, pruritus, diarrhea, alopecia, decreased weight, decreased
More news about: Astellas Pharma Inc.
Oct 20, 2025, 16:10 ET W. R. Berkley Corporation Reports Third Quarter 2025 Results
Residential - Alt A
More news about: W.R. BERKLEY CORPORATION
Oct 20, 2025, 12:30 ET iVANKY Introduces FusionDock Max 2: The First MacBook Dock for Thunderbolt 5 with Native Triple-Display Support
perform under heavy load." FusionDock Max 2 introduces a dual-chip architecture that pairs a Thunderbolt 5 controller with a DP-Alt chip, allowing users to connect up to two 6K displays and one 4K display natively — a first for MacBook docks. It also unlocks up to 120 Gbps of bandwidth,
More news about: iVANKY
Oct 20, 2025, 08:37 ET Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch
Hepatotoxicity LYMPHIR can cause hepatotoxicity. In the pooled safety population, elevated ALT occurred in 70% of patients, with Grade 3 ALT occurring in 22%; elevated AST occurred in 64% of patients, with Grade 3 AST elevation occurring in 9%. For Grade 3 events, median
More news about: Citius Oncology, Inc.
Oct 19, 2025, 10:30 ET Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer
pruritus (24%), and nausea (21%). The most common Grade 3 or 4 laboratory abnormalities (≥2%) were decreased albumin (8%), decreased sodium (7%), increased ALT (7%), decreased potassium (5%), decreased hemoglobin (3.8%), increased AST (3.8%), increased GGT (2.6%), and increased magnesium (2.6%).
More news about: Johnson & Johnson
Oct 18, 2025, 10:30 ET PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
aminotransferase (AST), increased creatinine, rash, increased glucose, PN, increased lipase, decreased lymphocytes, increased alanine aminotransferase (ALT), decreased hemoglobin, fatigue, decreased sodium, decreased phosphate, decreased albumin, pruritus, diarrhea, alopecia, decreased weight, decreased
More news about: Astellas Pharma Inc.
Oct 17, 2025, 08:00 ET Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment
increases in alanine aminotransferase (ALT) (2 to 6%) and aspartate aminotransferase (AST) (2 to 3%) were reported in patients receiving Verzenio. Across three clinical trials in 3559 patients (monarchE, MONARCH 2, MONARCH 3), the median time to onset of Grade ≥3 ALT increases ranged from 57 to 87
More news about: Eli Lilly and Company
Oct 17, 2025, 07:00 ET CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis
In ASPEN, there was an increase from baseline in average ALT, AST, and alkaline phosphatase levels at all time points from Week 4 through Week 56 in both BRINSUPRI 10 mg and 25 mg arms compared to placebo. The incidence of ALT >3X upper limit of normal (ULN) was 0%, 1.2%, and 0.9%; the incidence
More news about: Insmed Incorporated
Oct 16, 2025, 08:47 ET Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™
Hepatotoxicity LYMPHIR can cause hepatotoxicity. In the pooled safety population, elevated ALT occurred in 70% of patients, with Grade 3 ALT occurring in 22%; elevated AST occurred in 64% of patients, with Grade 3 AST elevation occurring in 9%. For Grade 3 events, median
More news about: Citius Oncology, Inc.
Oct 16, 2025, 08:00 ET TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care
failure. Elevated aspartate aminotransferase (AST) occurred in 34% of patients, with Grade 3 or 4 elevations in 1.2%. Elevated alanine aminotransferase (ALT) occurred in 28% of patients, with Grade 3 or 4 elevations in 1.8%. Elevated total bilirubin occurred in 6% of patients with Grade 3 or 4 elevations
More news about: Johnson & Johnson
Oct 16, 2025, 07:00 ET Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025
ElevationsIn ASPEN, there was an increase from baseline in average ALT, AST, and alkaline phosphatase levels at all time points from Week 4 through Week 52 in both BRINSUPRI 10 mg and 25 mg arms compared to placebo. The incidence of ALT >3X upper limit of normal (ULN) was 0%, 1.2%, and 0.9%; the incidence
More news about: Insmed Incorporated
Oct 15, 2025, 09:00 ET Helix GenoSphere™ Launches MASH-Enriched Cohort of Over 17,000 Linked Clinico-Genomic Records to Accelerate Drug Discovery and Development
Results for 10+ Disease Specific Labs: Includes liver function tests such as Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST), liver fibrosis markers, triglycerides, HbA1c, and more. Disease
More news about: Helix
Oct 15, 2025, 09:00 ET UNPACK '26: SLIK KOMMER VI TIL Å REISE I 2026, I FØLGE HOTELS.COM
Fra å sove i gamle fengsler til å hoppe fra hotell til hotell blir neste års reiser alt annet enn A4. OSLO, Norge,
More news about: Expedia
Oct 15, 2025, 09:00 ET UNPACK '26: HOTELS.COM AFSLØRER, HVORDAN REJSENDE VIL UDFORSKE VERDEN I 2026
periode i 2025. 3 Undersøgelsen Unpack '26 blev gennemført på vegne af Expedia Group af OnePoll, og i alt deltog 2000 danske voksne, der har rejst i deres fritid eller planlægger at gøre det i løbet af de kommende tre år.
More news about: Expedia
Oct 14, 2025, 22:00 ET Kontron、産業用コンピュータ新モデル「KBox E-430-AML/ADN/AMH/ADH」を発表 ― スマート・アプリケーション開発を支援
E-430-AML/ADNは2つのDisplayPortコネクタを搭載し、マルチ・ディスプレイ環境を簡単に構築できます。KBox E-430-AMH/ADHはHDMIとDisplayPortを各1基ずつ備え、主流の2種類の映像インターフェースに対応することで、幅広い用途に活用できます。さらに両モデルとも、DisplayPort Alt Modeに対応したUSB Type-Cコネクタを搭載し、USB-C対応タッチスクリーン・モニターを1本のケーブルで接続できます。 詳細はこちらをご覧ください：
More news about: Kontron
Oct 14, 2025, 22:00 ET 콘트론, 통합업체와 개발자가 스마트 애플리케이션을 구동하는 데 유용한 신형 산업용 컴퓨터 KBox E-430-AML/ADN/AMH/ADH 출시
커넥터가 장착되어 있다. KBox E-430-AMH/ADH에는 HDMI 커넥터 1개와 DisplayPort 커넥터 1개가 장착되어 있어 가장 널리 사용되는 두 가지 비디오 인터페이스에 연결할 수 있으므로 시스템 활용도가 극대화된다. 또한 두 제품 모두 DisplayPort Alt 모드를 지원하는 USB Type-C 커넥터를 탑재하고 있어 USB-C 연결 방식의 터치스크린 모니터를 하나의 USB-C 케이블로 연결해 사용할 수 있습니다. 자세한 내용은
More news about: Kontron
Oct 14, 2025, 08:38 ET Building the Purpose Capital of the World: Seattle Hosts (Re)Purpose Summit on Nov 12, 2025
Kenji López-Alt, NY Times bestselling author, chef, & food scientist
More news about: (Re)Purpose
Oct 14, 2025, 05:05 ET NxLite Raises $9.2M Series A to Expand Operations for Next-Generation Energy-Control Windows Coatings
The investment round was led by Crabtree Lane Alt, LLC, a Chicago-based active financial investor, and had participation from leading manufacturers in the door and window industry and venture capital
More news about: NxLite
Oct 13, 2025, 08:00 ET Calamos Revolutionizes Investor Access to Bitcoin, Launching the World's First Bitcoin Laddered Structured Protection ETFs
Calamos Laddered Bitcoin Structured Alt Protection ETF™ (CBOL) – Composed of 100% protected bitcoin ETFs Calamos Laddered Bitcoin 90 Series Structured Alt Protection ETF™ (CBXL) – Composed of 90% protected
More news about: Calamos Investments
Oct 13, 2025, 07:00 ET Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)
years, 8/29, 28%), pyrexia (overall, 6/38, 16%; those treated with age of symptom onset of ≤12 years, 6/29, 21%), increased alanine aminotransferase (ALT; overall, 6/38, 16%; those treated with age of symptom onset of ≤12 years, 5/29, 17%), and increased aspartate aminotransferase (AST; overall, 5/38,
More news about: UCB
Oct 13, 2025, 06:45 ET Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting
increases in alanine aminotransferase (ALT) (2 to 6%) and aspartate aminotransferase (AST) (2 to 3%) were reported in patients receiving Verzenio. Across three clinical trials in 3559 patients (monarchE, MONARCH 2, MONARCH 3), the median time to onset of Grade ≥3 ALT increases ranged from 57 to 87
More news about: Eli Lilly and Company
Oct 10, 2025, 14:28 ET PR Newswire Powers the AI Era, Embracing the Future of AI Search and Information Discovery
A: Yes, it's a critical component. While LLMs don't "see" images in a human sense, they meticulously analyze the associated text – like alt text, captions, and file names – to understand context. More importantly, multimedia dramatically increases engagement with
More news about: PR Newswire
Oct 10, 2025, 14:16 ET PR Newswire Powers the AI Era, Embracing the Future of AI Search and Information Discovery
A: Yes, it's a critical component. While LLMs don't "see" images in a human sense, they meticulously analyze the associated text – like alt text, captions, and file names – to understand context. More importantly, multimedia dramatically increases engagement with
More news about: PR Newswire
Oct 09, 2025, 10:06 ET Violife Collaborates with Cultural Icon Bozoma Saint John to Redefine What It Means to Eat Without Sacrifice
2024. *Nielsen, U.S. Unit Share of Alt Cream Cheese, latest 26 weeks, week ending 9/6/25. Violife® dairy free cream cheese: 41.2% Unit Share in such category. **Nielsen, U.S. Unit Share of Alt Cheese, latest 26 weeks, week ending 9/6/25. Violife® dairy
More news about: Flora Food Group USA
Oct 09, 2025, 09:30 ET HUBLOT Y DANIEL ARSHAM PRESENTAN EL MP-17 ARSHAM SPLASH: UNA FLUIDA EVOLUCIÓN DE LA RELOJERÍA ARTÍSTICA
Frecuencia (HZ): 3 (21 600 alt/h) Reserva de marcha: 240
More news about: Hublot SA